On November 10, 2026, Steven H. Stein, Chief Medical Officer & Head of Late-Stage Development at Incyte Corp. (INCY), executed a series of sales totaling approximately $21.75 million. Stein sold a combined 182,815 shares across multiple transactions at prices ranging from $118.27 to $119.66 per share.
These transactions occurred on November 6, 2026, with the aggregate value derived from the provided data. While insider sales can be motivated by various factors such as portfolio diversification, tax planning, or personal liquidity needs, the concentrated nature of these sales by a key executive may draw investor attention.